Curriculum Vitae

Curriculum VitaeROBERT G. GISH, M.D.219

Table of ContentsPagePROFESSIONAL INFORMATION A.LICENSURE & CERTIFICATIONS1BEDUCATION2C.POST GRADUATE EDUCATION2D.HONORS2E.NATIONAL FOUNDATION HONORS2F.SOCIETY MEMBERSHIPS2G.LANGUAGES2

BIOGRAPHY3-6

A.PERSONAL STATEMENT5B.EXPANDED RESEARCH5C.PRESS RELEASE - HEPATITIS B FOUNDATION6D.FACULTY APPOINTMENTS7-8E.EMPLOYMENT AND STAFF POSITIONS8-10F.STATE OF CALIFORNIA CONSULTANT POSITIONS10G.CONSULTANT POSITIONS10H.BUSINESS POSITIONS11I..HRESEARCH SUPPORT12-30J.UCSD RESEARCH / ADVISORY31-32K.COINVESTIGATOR: GASTROINTESTINAL TRIALS32-33

TEACHING ACTIVITIES34-35A. COMMITTEES35-40B. BOARD ACTIVITIES41-43C. EDITORIAL ACTIVITIES44D. MENTEE LIST45-47E. CLINICAL EXAM SESSIONS47

PUBLICATIONSA. PEER REVIEW ORIGINAL PUBLICATIONS48-62B. SUBMITTED FOR PUBLICATION63C. REVIEW ARTICLES64-67D. PUBLIC POLICY ORIGINAL MANUSCRIPT67E. NEWLETTERS68F. BOOK CHAPTER & EDITORIALS68-72G. CASE REPORTS & LETTER TO THE EDITORS72H. EDITOR / REVIEWER73-76I. UCSD77J. ABSTRACTS78-108

iPage

OTHER

CME PRESENTATIONS AND PUBLICATIONS109-115FEDERAL AND STATE HEARINGS116EDUCATIONAL EVENTS116SPECIAL COURSES ATTENDED117COMMUNITY SERVICE and MEDIA APPEARANCES118-126INTERNATIONAL Community Programs127INTERNET SITES AND PUBLICATIONS128INVITED LECTURES: NATIONAL AND INTERNATIONAL129-139INVITED LECTURES: REGIONAL140-191AWARDS, CERTIFICATES, AND HONORS192-193CONSULTANT: ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES194-213Historical PRACTICE ADDRESSES and OUTREACH SITES214-215RESEARCH SUMMARY216-217former practice leadership218

disclosures219PHARMACEUTICAL COMPANY RELATIONSHIPS219SPEAKERS BUREAU219

iiCurriculum Vitae

ROBERT G. GISH, M.D.

PROFESSIONAL INFORMATION

8/31/2013 PresentRobert G. Gish MD, PrincipalRobert G. Gish, Consultants LLC6022 La Jolla Mesa DriveLa Jolla, California 92037Cell phone:1 858 229 9865Fax:1 858 886 7093Email:rgish@robertgish.comWeb address:robertgish.com

10/1/2013 Present(Adjunct) Professor of Clinical MedicineUniversity of Nevada, Las Vegas

10/1/2013 PresentSenior Medical DirectorSt. Josephs Hospital and Medical Center Phoenix, Arizona

1/31/2014 PresentMedical Director Hepatitis B Foundation http://hepb.org/index.html

5/1/2014 - PresentClincial Professor of Medicine (Consultant) Stanford Hospital and Medical CenterStanford, California

PERSONAL INFORMATION

Date of Birth: September 18, 1955SSN: Available upon requestMarital Status: MarriedHome Address: San Diego, CaliforniaBirthplace: Chicago, IllinoisCitizenship: U.S.A.

LICENSURE

State of California, G-045632State of Nevada, 772112State of Arizona, 48551

BOARD CERTIFICATION

1984Internal Medicine ABIM 901811987Gastroenterology ABIM 90181 (MOC active)2007CAQ Liver Transplantation ABIM 90181

EDUCATION

9/1/1973 6/15/1977Pharmaceutical SciencesUniversity of KansasLawrence, Kansas

9/1/1977 6/15/1980Medical DoctorUniversity of Kansas School of MedicineKansas City, Kansas

POSTGRADUATE EDUCATION

6/1/1980 5/30/1981Internship in Internal MedicineUniversity of California, San DiegoSan Diego, California

6/1/1981 6/30/1983Residency in Internal Medicine`University of California, San DiegoSan Diego, California

7/1/1984 5/30/1988Fellowship in Gastroenterology and HepatologyUniversity of California, Los AngelesLos Angeles, California

NATIONAL HONORSAlpha Omega Alpha

NATIONAL FOUNDATION HONORS

2002Salute to Excellence: American Liver Foundation, 2/9/2002

SOCIETY MEMBERSHIPS

American Association for the Study of Liver DiseaseAmerican Gastroenterological AssociationAmerican Society of Transplant PhysiciansAmerican College of PhysiciansAsia Pacific Association for the Study of the LiverCalifornia Medical AssociationEuropean Association for the Study of the LiverInternational Liver Cancer AssociationAmerican Liver FoundationAmerican Transplant SocietyInternational Coalition of Hepatology Educators

LANGUAGES

EnglishSpanishVietnameseFrench

Curriculum VitaeROBERT G. GISH, M.D.12

BIOGRAPHY

Dr. Gish began his medical training in 1974 when he was enrolled into the Pharmacy School at the University of Kansas. He transferred to the University of Kansas Medical School in 1977 and finished his MD degree in 1980.

Dr. Gish went on to complete a 3 year Internal Medicine residency at the University of California, San Diego and a 4 year Gastroenterology and Hepatology fellowship at the University of California Los Angeles during which time he was awarded the NIH Physician Scientist Award to study calcium signaling in liver cells.

After completing his training, Dr. Gish moved to San Francisco and took a position at the California Pacific Medical Center (formerly known as Pacific Presbyterian Hospital). He became the Co- Medical Director of the Liver Transplant Program in 1988 and then the Medical Director of the Liver Transplant Program in 1994. In that role he developed an outreach program that eventually served over 35,000 patients in the Northern California and Nevada regions, and made the CPMC a leading liver transplant center.

Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio artificial liver, and public policy especially related to liver cancer, liver transplantation and viral hepatitis. Although his primary research focus is clinical research, he frequently collaborates with basic scientists in his research activities. He has published more than 500 original articles, review articles, abstracts and book chapters.

Dr. Gish is also actively involved in numerous professional societies, and is a long-term member of the American Association for the Study of Liver Disease, European Association for the Study of Liver Disease, Asian Pacific Association for the Study of the Liver, and the American Society of Transplant Physicians.

He is a fellow of both the American College of Physicians and a long-term member of the American Association for the Study of Liver Disease. Dr. Gish has served on the editorial boards of American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases and Sciences, Gastroenterology, Hepatology, Liver Transplantation and Surgery, and Journal of Viral Hepatitis. He has co-authored a public health policy for liver health in Vietnam and is also assisting with the development of health care policies in Armenia and the Philippines.

In December 2010, Dr. Gish moved to San Diego to join the faculty of UCSD as a Clinical Professor of Medicine, Section Chief of Hepatology, and Director of the Center of Excellence for Hepatobiliary Disease and Abdominal Transplantation (C.H.A.T.).

In September of 2013, Dr. Gish left UCSD to form a consulting company, Robert G. Gish Consultants LLC to provide consultative support to Hepatology Centers and Liver Transplant Programs who wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. In September of 2013, Dr Gish joined Dr Manch at St Josephs Hospital and Medical Center to start a liver and liver transplant center which continues to be an ogoing venture. On April 1, 2014, Dr Gish joined the Stanford

BIOGRAPHY: Continued

Department of Medicine, Division of Gastroenterology and Hepatology and Liver Transplant Service Line as a Staff Physician with major roles in inreach and outreach as well as program development. Over the years of 2012 to 2014, Dr Gish has been and continues to be very active with the National Viral Hepatitis Round Table (NVHR) a patient and community advocacy non-profit organization. In February of 2014, Dr Gish joined the Hepatitis B Foundation, (HBF) as their medical director to lend his policy, advocacy and clinical science skills to their armamentarium,

Today, Dr. Gish is a Clinical Professor of Medicine (Adjunct) at the University of Nevada in Las Vegas where he continues to teach and is a senior consultant at St Josephs Medical Center in Phoenix. And Clinical Professor of Medicine at Stanford University (Consultant)

LIVER CENTERS AND LIVER TRANSPLANT PROGRAMS

Dr. Gish became the Co-Medical Director of the Liver Transplant Program at the California Pacific Medical Center in 1988. He developed an outreach program that now serves over 35,000 patients in Northern California and Nevada, making CPMC a leading liver transplant center. Dr. Gish joined the faculty of University of California San Diego in several capacities, including Director of the Center for Hepatobiliary Disease and Abdominal Transplantation. He also became Director of Clinical Hepatology at UCSD in 2010. His research on Regional Review Boards may also change public policies on liver transplants in the United States. This research supports the replacement of the current RRB system with a national review board that uses clinical expertise to assign priorities. The goal of this system is to allocate organs equitably while improving compliance with the HHS Final Rule. His appointment with the Liver Transplant Program and Department of Medicine at Stanford University began on April 30, 2014.

RESEARCH

Dr. Gishs pharmaceutical research includes a 2011 Phase III study on the effects of BI 201335, pegylated interferon-a and ribavirin on patients infected with genotype 1 chronic hepatitis C. He is also the principle investigator in an ongoing study on screening for viral hepatitis and its economic effects on healthcare. Another study currently being conducted by Dr. Gish involves the analysis of liver patients at UCSD.

Dr. Gish was the principle investigator in a study that was started in 2012 to investigate the effects of PSI-352938, PSE-7977 and Ribavirin in patients with Chronic HCV. He is also currently investigating the challenges of educating Asians in San Diego County on Hepatitis B in a study that began in 2012.

Dr. Gish was an investigator in studies that led to the development of tests for HBV and HCV and most recently a 2005 study on DNA HBV genotyping and molecular profiling in newly recruited, HBV and HCV patients. He was also an investigator in a 2006 study that used molecular signatures to predict interferon response in patients infected with Hepatitis C.

Dr Gishs research now includes co-leading a research program with Arrowhead Pharmaceuticals on iRNA treatment of HBV infection.

BIOGRAPHY: Continued

HEALTH POLICY AND PATIENT ADVOCACY

Dr. Gish has been involved with patient care and patient advocacy groups dating back to 1988 when he became involved with the American Liver Foundation. Since that time, he has been active with a number of organizations including the National Viral Hepatitis Roundtable, Viral Hepatitis Action Coalition, the Fair Foundation, Center for Eradication of Viral Hepatitis/Asia Pacific Organization, HEP- DART, World Health Organization, Centers for Disease Control, Hepatitis B Free (San Francisco and San Diego), Hepatitis B Foundation, Hepatitis C Caring Ambassadors, Viral Hepatitis Foundation, and Hepatitis Foundation for Vietnam. Dr. Gishs international advocacy career focuses on public policy in Vietnam, Philippines, and Armenia. His team wrote a white paper on Health Care and Liver Health in Vietnam that was published in a peer-reviewed publication. Additional projects in Vietnam and the Philippines include protocols that advance screening for viral hepatitis and link- age to care, as well as global liver health issues including obesity, fatty liver, and alcohol induced liver disease. The newest addition to Dr. Gishs global health policy work is in Armenia, where he is developing a white paper for that countrys 5-year Liver Health Policy.

PERSONAL STATEMENT

My clinical research and studies focus on viral hepatitis, liver transplant, bioartificial liver, public policy especially related to liver transplantation and viral hepatitis. Clinical trials for a variety of antiviral therapies and new bioartificial livers systems will continue to be a major focus of my practice. We will use databases to help uncover associations between liver cancer and certain cancer biomarkers. In addition we will be building a multidisciplinary liver cancer program and willintegrate models of HCC signaling into our program. My background includes training in viral hepatitis clinical trials and liver cancer trials. I plan to have a focus on biomarkers for liver cancer to help guide treatment decisions and therapies. I have 25 years of experience as a clinician and clinical investigator in the realm of liver disease, liver transplant and liver cancer. I do a variety of educational programs for Pharma including promotional talks that are highly regulated by the FDA and the Pharma Code: these funds are all recycled into research, education, policy, philanthropy and supporting international health care.

EXPANDED RESEARCH

Dr. Gishs work focuses on the epidemiology of liver disease, biomarkers for liver disease and multi-targeted therapies for liver cancer such as protein kinase inhibitors, fibroblast growth factors and iRNA technologies to treat viral hepatitis. His research also includes the diagnosis and treatment of liver failure, liver transplantation, and viral hepatitis, both B and C variants. Recent clinical studies have focused on the Hepatitis B Virus within the Asian population at large as well as exosomes, liver failure, bioartifical livers and international health policy.

BIOGRAPHY: Continued

PRESS RELEASE February 2014

Hepatitis B Foundation Welcomes Dr. Robert Gish as Medical Director

Renowned leader in the field of liver disease takes on new role leading advocacy and research

DOYLESTOWN, Pa. (February 2014) The Hepatitis B Foundation (www.hepb.org), the only national nonprofit organization solely dedicated to finding a cure for hepatitis B, is pleased to announce that Robert G. Gish, M.D., became the foundations medical director on Jan. 30, 2014. An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has made invaluable contributions to the understanding and treatment of hepatitis B, which is the worlds leading cause of liver cancer. A longtime supporter of the foundations mission and a member of the Scientific Advisory Board, Dr. Gishs new role will further strengthen its research and advocacy efforts worldwide. We are delighted to welcome Dr. Gish to our board, said Dr. W. Thomas London, senior member emeritus of Fox Chase Cancer Center and vice president of the board of directors of the Hepatitis B Foundation. He has long been a leader in the field and has extensive experience in the conduct of clinical trials of new drugs to combat chronic hepatitis B. His leadership as medical director will help us advance the treatment and prevent the severe consequences of this potentially deadly disease. After receiving his medical degree in 1980, Dr. Gish quickly developed a keen interest in liver health, focusing his research on investigation of viral hepatitis B and C. He went on to become medical director of the liver transplant program at California Pacific Medical Center in 1994, developing an outreach program that eventually served more than 35,000 patients in northern California and Nevada and made the medical center a leading liver transplant center. Over the course of his career, Dr. Gish has published more than 600 original articles, abstracts and book chapters and more than 120 peer-reviewed publications. Today, he is a clinical professor of Medicine at the University of Nevada in Las Vegas, where he continues to teach, and is a senior consultant at St. Josephs Medical Center in Phoenix. In 2013, he formed Robert G. Gish Consultants LLC to support liver health and transplant programs with operations, outreach, compliance, financial planning and program development in the U.S. and Asia. Dr. Gishs background is a perfect fit for the work we do here at the Foundation and our Baruch S. Blumberg Institute, said Dr. Timothy Block, president of the Hepatitis B Foundation and also a professor of Microbiology at Drexel University. We are honored that Dr. Gish has agreed to become our medical director and look forward to many years of collaboration so we can finally put an end to this serious liver infection. To learn more about Dr. Robert Gish, visit his website.

FACULTY APPOINTMENTS

*Please note: The following dates are best estimates due to lack of evidenced documentation:

7/1/1983 6/30/1984Emergency Room AssociateClaremont HospitalClaremont, California

6/1/1985 5/30/1988Research AssociateDivision of GastroenterologyUniversity of California, Los AngelesLos Angeles, California

9/11988 6/1/1993Research AssociateMedical Research InstituteCalifornia Pacific Medical CenterUniversity of the PacificSan Francisco, California

9/1/1991 7/2/1996Assistant Clinical Professor of MedicineUniversity of California, DavisSacramento, California

7/1/1991 6/30/1996Valley Children's HospitalLiver Disease ProgramFresno, California

7/1/1993 6/30/1998Merced Community HospitalFamily Medicine ProgramUniversity of California, DavisSacramento, California

7/1/1994 6/30/1998Assistant Clinical Professor of MedicineUniversity of Nevada, RenoReno, Nevada

7/1/1998 6/30/2005Associate Clinical Professor of MedicineUniversity of Nevada, RenoReno, Nevada

7/1/2005 6/30/2006Clinical Professor of MedicineUniversity of Nevada, Las Vegas, Nevada

8/1/1995 1/1/2010Medical Director of Liver Transplant ProgramCalifornia Pacific Medical CenterSan Francisco, California

9/1/1996 6/1/1999Assistant Clinical Professor of MedicineUniversity of California, San FranciscoSan Francisco, California

FACULTY APPOINTMENTS: Continued

7/30/1999 6/30/2009Associate Clinical Professor of MedicineUniversity of California, San FranciscoSan Francisco, California

7/1/2009 8/30/2010Clinical Professor of MedicineUniversity of California, San FranciscoSan Francisco, California

9/1/2010 8/30/2013Clinical Professor of MedicineUniversity of California, School of MedicineSan Diego, California

1/1/2014 PresentClinical Professor, Department of Internal Medicine, AdjucntUniversity of Nevada School of Medicine, Las Vegas, Nevada

EMPLOYMENT AND STAFF POSITIONS

1975 1977Research AssociateMcCollum LaboratoriesUniversity of KansasLawrence, Kansas

1982 1983Per diem PhysicianMedicus Medical GroupSan Diego, California

1982 1983Per diem PhysicianKaiser PermanenteSan Diego, California

1982 1983On call MD: Life Flight-Critical Air TransportSan Diego, California

1983 1984Per diem PhysicianPioneer Memorial HospitalBrawley, California

1983 1984Emergency Clinic and Medical Doctor at Clarmmont HospitalIndustrial Medical CentersSan Diego, California

EMPLOYMENT AND STAFF POSITIONS: Continued

1984 1986Emergency Physician: Serra Memorial Hospital Emergency MedicineSun Valley, California

1986 1988ConsultantSherman Oaks Community HospitalSherman Oaks, California

1987ConsultantPhillip Edelman, M.D.Occupational MedicineOrange, California

1987ConsultantWashington Medical CenterCulver City, California

1987 1988Consultant Valley PresbyterianVan Nuys, California

1988Staff PhysicianOliveview Medical CenterSylmar, California1988ConsultantWest Hills Medical CenterConoga Park, California

1988 1989ConsultantMt. Zion Medical Center San Francisco, California

1990 1991ConsultantSeton Medical CenterDaly City, California

1990 1995ConsultantValley Children's Hospital Fresno, California

1993 2006ConsultantEnloe Hospital, Chico, California

2002 2009ConsultantSunrise HospitalLas Vegas, NV

EMPLOYMENT AND STAFF POSITIONS: Continued

1988 2010Staff PhysicianCalifornia Pacific Medical CenterSan Francisco, California

2009 2010PhysicianSt. Lukes HospitalSan Francisco, California

1991 2010ConsultantHighland Hospital Oakland, California

1996 2010ConsultantMedical Staff, Department of MedicineJohn Muir Medical CenterWalnut Creek, California

1997 2006ConsultantAlta Bates Medical CenterMedicine and Family PracticeBerkeley, California

2003 2010PhysicianSaint Marys Medical CenterSan Francisco, California

2010 2013Medical Director of Center for Hepatobiliary Disease and Abdominal Transplantation (CHAT)Chief of HepatologyUniversity of California, San Diego San Diego, California

2014 - PresentMedical Director, Staff Physician Stanford Hospital and Medical CenterStanford, CA

STATE OF CALIFORNIA CONSULTANT POSITIONS

1996State of CaliforniaDepartment of CorrectionsInfectious Disease Advisory Board

CONSULTANT POSITIONS

2010 PresentFounding MemberCEVHAP (Coalition to Eradicate Viral Hepatitis in Asia Pacific).Singapore

2012 2014Advisory Board/Steering Committee, National Viral Hepatitis Roundtable

2013 2014Executive Committee Vice Chair, NVHR

BUSINESS POSITIONS

1999 2000President and TreasurerPacific Hepatology and Gastroenterology Medical Group, P.C.San Francisco, California

1999 2001President and CEO Hepahope Corporation San Francisco, California

2000 2005PresidentPacific Hepatology and Gastroenterology Medical Group, P.C.San Francisco, California

2009 PresentPresident, Pacific Health Consortium LLC

1988 2010Office address: California Pacific Medical Center2340 Clay StreetSan Francisco, California 94115

2010 2013U.C. San DiegoMedical Director of Center for Hepatobiliary Disease and Abdominal Transplantation (CHAT)Chief of HepatologyProfessor of Medicine350 Dickinson Street, Suite 342San Diego, California

8/31/2013 Robert G. Gish MDPresentRobert G. Gish Consultants, LLCBusiness address: 6022 La Jolla Mesa DriveSan Diego, CA 92037Cell phone: 1 858 229 9865Email: rgish@robertgish.comWebsite: robertgish.comCurriculum VitaeROBERT G. GISH, M.D.3

RESEARCH SUPPORT

1975 1977Co-Investigator: NIH Grant #GM 22357. Ionization Kinetics of Carbon Acids. University of Kansas. Grant award: $70,000.

1985 1988Principle Investigator: National Institute of Environmental Health Sciences Physician Scientist Award. Grant award: $210,000.

1993 1995Co-Investigator: Amgen grant. A Phase III, Randomized, Double-Blind Controlled Trial of Recombinant Methionyl Interferon Consensus (r-tetIFN-Con1) in Patients with Chronic Hepatitis C Virus (HCV) Infection. California Pacific Medical Center. Grant award: $187,604.

1993 1994Co-Investigator: Loewy Fund grant. Development and Validation of a Standardized Interview for the Detection of Alcoholism in Patients Referred for Liver Transplantation. California Pacific Medical Center. Grant award: $6,487.

1993 1998CoInvestigator: NIH grant. Cytokines and Human Autoimmune Liver Disease. Grant award: $579,800.

1994Principle Investigator: Syntex grant. Ganciclovir for the Treatment of Hepatitis B after Organ Transplantation. Grant award: $10,000.

1994Principle Investigator: Schering Corporation grant. Interferon alfa-2b: Dose Escalation and Taper for the Treatment of Hepatitis C. Grant award: $15,000.

1995Principle Investigator: PRI grant. Natural History of Hepatitis B. Grant award: $10,000.

1995Co-Investigator: Chiron grant. Beta-Interferon for Retreatment of Hepatitis C. Grant award: $30,000.

1995 1997Principle Investigator: Schering-Plough grant. Hepatitis C Treatment with Interferon with or without Phlebotomy. Grant award: $25,000.

1995 1997Co-investigator: GlaxoWellcome grant. Study P110-008- Tucaresol Dose Escalation Drug Study for Hepatitis B. Grant award: $35,000.

1996 1997Co-Investigator: GlaxoWellcome grant. Study NUCA 3011- A Placebo-Controlled Study of Lamivudine and Intron-A in Patients with Chronic Hepatitis B Infection who are Interferon Non-Responders. Grant award: $8,000.

1996 1997Co-Investigator: GlaxoWellcome grant. Study NUCA3010- A Study of Lamivudine or Placebo in Patients with Chronic Hepatitis B Infection who are Treatment Naive. Grant award: $10,000.

1996 1997Co-Investigator: GlaxoWellcome grant. Study NUCA3005- Lamivudine Open Label Program for Treatment of Patients with Hepatitis B Viral Infection Post-Liver Transplantation. Grant award: $20,000.

1996 1997Co-Investigator: GlaxoWellcome grant. Study NUCA2006- A Pilot Study to Assess the Safety and Efficacy of Lamivudine During the Course of Liver Transplantation for Patients with Chronic Hepatitis B Infection (nave study). Grant award: $35,000.

1996 2001Principle Investigator: GlaxoWellcome grant. Study NUCA3017- A Study of Extended LamivudineTtreatment for Hepatitis B Patients Previously Enrolled in Phase II or Phase III Lamivudine Trials. Grant award: $80,000.

1996 1997Co-Investigator: Schering-Plough grant. Study C95-144- Interferon with or without Ribavirin in Hepatitis C Patients with Relapse after Interferon. Grant award: $158,000.

1996 1997Co-Investigator: Schering-Plough grant. Study C95-132- IntronA Monotherapy vs. IntronA + Ribavirin for Treatment of Chronic Hepatitis C in Interferon-naive Patients. Grant award: $178,000.

Curriculum VitaeROBERT G. GISH, M.D.22

RESEARCH SUPPORT: Continued

1996 1998Principle Investigator: Schering-Plough grant. Interferon with Ribavirin for Interferon Failure in Hepatitis C Patients. Grant award: $550,000.

1996 1997Principle Investigator: Ciba Corning grant. Lab study of Mx protein as a Marker for Injection Therapy. Grant award: $5,000.

1996 1999Principle Investigator: GlaxoWellcome grant. Study NUCA3021- Lamivudine Compassionate Use Treatment Program for Subjects of Three Life-Threatening Forms of Hepatitis B Infection.

1997 2000Principle Investigator: Otsuka America Pharmaceutical Inc. Grant. Study 156-96-203; Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy, Safety and Pharmacokinetics Study of OPC 41061 in Hospitalized Patients with Hyponatremia, Secondary to Liver Disease. Grant award: $150,000.

1997 2002Co-investigator: Roche BioScience grant. Study MYCO 2642- A Randomized, Double-Blind, Comparative Study of the Efficacy and Safety of Intravenous and Oral Mycophenolate Mofetil and Azathioprine, Each in Combination with Cyclosporine (Neoral) and Corticosteroids in Liver Transplant Recipients. Grant award: $176,000.

1997 2002Principle Investigator: GlaxoWellcome grant. Study NUCA 3016- A Long-term Epidemiologic Study of Patients who have Evidence of Possible Durable Response to Lamivudine in Phase II or Phase III Trials of Lamivudine. Grant award: $21,000.

1998 2000Principle Investigator: Triangle Pharmaceuticals grant. Phase I Clinical Trial of FTC for Patients who have Chronic HBV Infection. Grant award: $300,000. 1998 2001Principle Investigator: Triangle Pharmaceuticals grant. Phase II Rollover Clinical Trial of FTC for Patients who have Chronic HBV Infection. Grant award: $200,000.

1998 1999Principle Investigator: Bristol-Myers Squibb grant. Lobucavir vs. Interferon for patients who have not undergone previous Treatment with Interferon Therapy. Grant award: $75,000.

1999 2000Principle Investigator: Bristol-Myers Squibb grant. 200475 vs. Interferon for patients who have not undergone previous treatment with Interferon therapy. Grant award: $85,000.

1998 1999Co-investigator: Bristol-Myers Squibb grant. Lobucavir for Patients who have Failed Previous Treatment with Interferon Therapy. Grant award: $75,000.

1997 1998Co-investigator: Matrix Pharmaceuticals grant. Intratumoral Injection of Cis-Platinum/Bovine Collagen for theTreatment of Hepatocellular Carcinoma and Metastatic Colon Cancer. Grant award: $30,000.

1998 PresentPrincipal Investigator: Schering-Plough grant. Interferon/Ribavirin Treatment of Non-Responders and Relapsers. Grant award: $750,000.

1998 2000Principle Investigator: Schering-Plough grant. Study C98-169- Comparison of Intron A Induction Therapy + Rebetol vs. Intron A + Rebetol for the Treatment of Adult Naive Subjects with Chronic Hepatitis C Infected with HCV Genotypes 1, 2, 3, or 2/3. Grant award: $59,000.

1998 2001Principle Investigator: Hoffmann-LaRoche grant. Study NV15496C- A Phase III Open-label, Randomized, Multicenter, Parallel Dose Efficacy and Safety Study Comparing Pegylated-Interferon -2a (RO 25-8310) to a Standard Regimen of Roferon A in the Treatment of Patients with Chronic Hepatitis C. Grant award: $148,000.

1997 2001Principle Investigator: Schering-Plough grant. Study C96-318-Treatment of Relapse in Patients with Chronic Hepatitis C Comparing Intron A Monotherapy vs. IntronA + Ribavirin. Grant award: $20,000.

1998 2001Principle Investigator: An open-label, single arm Study to Evaluate the Combination of Zenapax (daclizumab) and CellCept (mycophenolate mofetil) with Corticosteroids in the Prevention of Acute Rejection in Primary Liver transplant Recipients. Roche Pharmaceuticals. Grant award: $17,500.

1997 1999Principle Investigator: Schering-Plough grant. Study C97-010- Comparison of Peg-interferon vs. Intron A for Treatment of Adult Subjects with Chronic Hepatitis C not Previously Treated with Interferon: Dose-finding study. Grant award: $105,000.1999 2002Principle Investigator: Hoffmann-LaRoche grant. Study # NV15801- A phase III,Rrandomized, Multicenter, Efficacy and Safety Study Comparing the Combination of Pegylated-interferon -2a (Ro 25-8310) and Ribavirin with Rebetron A in the Treatment of Patients with Chronic Hepatitis C. Grant award: $68,000.

1999 2002Principle Investigator: Hoffmann-LaRoche grant. Study NR15994- A randomized, open-label, multicenter, efficacy and safety Study of Pegasys plus Ribavirin, Pegasys plus CellCept, Pegasys plus Amantadine, or Pegasys plus Amantadine plus Ribavirin in Patients with Chronic HCV Infection who have not Responded to at least 12 Weeks of Treatment with Rebetron. Grant award: $75,000.

1999 2002Principle Investigator: Gilead grant. Study GS98-437- A double- blind, randomized, placebo-controlled Study of Adefovir Dipivoxil for the Treatment of Patients with HBeAg+ Chronic Hepatitis B Virus Infection. Grant award: $106,000.

1999 2006Principle Investigator: Gilead Pharmaceuticals grant. Phase III & Rollover, Double-blind, randomized, placebo-controlled Study of Adefovir Dipivoxil for Treatment of Patients with HBeAg+ Chronic Hepatitis B Virus Infection with Open Label Long Term Follow Up of Safety, Efficacy, and Resistance of Adefovir. Grant award: $143,323.

2000 2001Principle Investigator: Gilead grant. Study 472- Pharmacokinetics study (PK) of 48 weeks treatment with adefovir 10mg/day for HBV infected, nucleoside treatment-nave patients with compensated liver disease.

2000Sub-Investigator: Bristol-Meyers Squibb grant. Long-Term rollover, assessment of safety and antiviral activity of open-label entecavir plus lamivudine in chronic hepatitis B patients who have viremia on monotherapy in other entecavir trials. Grant award: $32,571.

2000 2005Sub-Investigator: Bristol-Meyers Squibb grant. A phase III study of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in Adults with Chronic Hepatitis B Infection who are Positive for Hepatitis B E Antigen. Grant award: $75,867.

2000 2005Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Study of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in Adults with Chronic Hepatitis B Infection who are Negative for Hepatitis B E-Antigen. Grant award: $29,911. 2000 2005Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Study of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in Adults with Chronic Hepatitis B Infection who are Negative for Hepatitis B E-Antigen. Grant award: $40,048.

2000 2005Sub-Investigator: Bristol-Meyers Squibb. Long-term Assessment of Treatment Outcomes with Entecavir and Lamivudine for Chronic Hepatitis B Infection in Patients who have Enrolled in Phase III Entecavir Trials. Grant award: $3,524.

2000 2005Principle Investigator: Bristol-Meyers Squibb. Decompensated, Comparison of the Efficacy and Safety of Entecavir vs. Adefovir in Subjects Chronically Infected with Hepatitis B virus with Evidence of Lamivudine Resistance and Hepatic Decompensation. Grant award: $80,150.

2001Principle Investigator: GlaxoSmithKline grant. Study Nuc2094 - Lamivudine and Adefovir Combination for the Treatment of Chronic HBV Infection.

2001 2002Principle Investigator: Scripps Consortium grant. Hepatitis C Registry. Grant award: $5,000.

2001 2002Principle Investigator: Bayer Pharmaceuticals grant. HCV 3.0 assay development. Grant award: $6,000.

2001 2002Co-Investigator: BioMeasure, Inc., grant. Lanreotide Study for the Study of Acute GI Bleeding in Portal Hypertension. Grant award: $40,000. 2001 2002Principle Investigator: Bristol-Meyers Squibb grant. Study 014-020- Entecavir vs. Lamivudine (52 weeks therapy) in Adult Patients with Chronic Hepatitis B who are Positive for Hepatitis B e-Antigen and Nave to Previous Therapy. 2001 2002Principle Investigator: Roceh Pharmaceuticals: 8 weeks of Peg-Interferon +/- Ribavirin vs. Roferon 3 MU TIW + Ribavirin for Patients with Chronic Hepatitis C Co-infected with HIV, Nave to Interferon Therapy.

2001 2002Sub-Investigator: Physician initiated study: Hepatitis Resource Network. Peg-interferon -2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-infected Persons not Previously Treated with Interferon.

2001 2002Sub-Investigator: National Hemochromatosis Transplant Registry grant. Prevalence of Hepatic Iron Overload and HFE Mutations among Patients Undergoing Orthotopic Liver Transplantation (OLT): Interim Results from the National Hemochromatosis Transplant Registry (NHTR) NIH.

2001 2006Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter, double-blinded study in patients with compensated non-cirrhosis due to chronic hepatitis C who are non-responders to prior interferon alfa + ribaviron therapy, comparing treatment with thymosin + peg-interferon with peg-interferon + placebo. Grant award: $289,756.

2001 2008Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter, double-blinded study in patients with compensated cirrhosis due to chronic hepatitis C who are non-responders to prior interferon alfa + ribaviron therapy, comparing treatment with thymosin + peg-interferon with peg-interferon + placebo. Grant award: $240,869.

2001 2005Sub-Investigator: Hoffman-LaRoche grant. A Phase III partially double-blind study Evaluating the Efficacy and Safety of 40kD Branched Pegylated Interferon Combined withPlacebo or Lamivudine vs. Lamivudine in HBeAg- Positive Patients with Chronic Hepatitis B. Grant award: $45,579.

2001 2006Principle Investigator: Schering-Plough grant. Long term follow up Protocol to Assess Subjects after Completing 24 weeks of Schering-Plough Research Institute (SPRI) Clinical Trial for Chronic Hepatitis C. Grant award: $19,200.

2001 2005Principle Investigator: Schering-Plough grant. Comparison of peg-interferon plus ribavirin given as a fixed dose or on a weight optimized basis for treatment of chronic hepatitis C in previously untreated adult subjects. Grant award: $41,950.

2002 2004Principle Investigator: Roche Pharmaceuticals grant. A phase III partially double-blinded Study Evaluating the Efficacy and Safety of Pegasys with Placebo or Lamivudine Versus Lamivudine in HBeAg-PositivePpatients with Chronic Hepatitis B.

2002Principle Investigator: Ortho-Biotech grant. Procrit vs. Placebo weekly to treat anemia for patients taking ribavirin + interferon or peg-interferon.

2002Principle Investigator: Akros Pharma grant. A randomized, double-blind placebo-controlled, ascending dose Study of the Safety, Tolerability, Pharmacokinetics, andPpharmacodynamics of JTK-003 inPpatients with Chronic Hepatitis C Infection for Non-responders to Previous Therapy.

2002 2003Principle Investigator: ICN pharmaceuticals/Ribapharm grant. A Phase I multiple-dose astudy to evaluate safety, tolerability, and pharmacokinetics of viramidine for patients with compensated HCV.

2002Principle Investigator: Chiron grant. Randomized, placebo-controlled study of the safety and efficacy of HBV/MF59 (vaccine) alone or in combination with lamivudine.

2002 2003Principle Investigator: Bristol-Meyers Squibb grant. Entecavir vs. Lamivudine (52 weeks therapy) in Adult Patients with Chronic Pepatitis B who have had an Incomplete Response to Lamivudine Therapy.

2002 2005Principle Investigator: SciClone Pharmaceuticals grant. Thymosin for HCV Non-responders Comparing Treatment with Thymosin Alpha 1 + Peg-interferon Alpha-2a with Peg-interferon Alpha-2a + Placebo (Study 1: noncirrhotic; Study 2: cirrhotic).

2002 2005Co-Investigator: NIH grant. Recurrent Hepatitis B after Liver Transplant. Grant award: $32,705.

2002 2005Sub-Investigator: Roche Pharmaceuticals. A randomized, open label, multi-center, pilot study of Pegasys and Epivir-HBV as Initial Treatment of HBeAg- Negative Chronic Hepatitis B Infection. Grant award: $29,644.

2002 2003Principle Investigator: Intermune grant. Double-blind, randomized, placebo-controlled Study of the Safety and Anti-fibrotic Efficacy of Gamma Interferon in Patients with Severe Liver Fibrosis or Cirrhosis due to HCV.

2002 2003Sub-investigator: Schering Corp. Comparison of Peg-interferon Alfa-2b plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis in Previously Untreated Adult Patients.

2002 2004Principle Investigator: SciClone Pharmaceuticals grant. Trial of zadaxin with transarterial chemoembolization in patients with unresectable hepatocellular chemoembolization with or without zadaxin therapy for 6 months. Award $240,000

2002 2003Principle Investigator: ICN pharmaceuticals/Ribapharm grant. A Phase II randomized Study to Evaluate the Efficacy of Viramidine for Patients with Compensated HCV.

2002 2003Principle Investigator: Eximias Pharmaceuticals. Thymataq vs. Doxorubicin for the Treatment of HCC. Grant award: $240,000

2002 2005Principle Investigator: Valeant Pharmaceuticals grant. Phase II dose-ranging Study of Viramidine in Combination with Pegasys in Treatment-nave Subjects with Chronic Hepatitis C Infection. Grant award: $292,559.

2002 2005Sub-Investigator: Idenix Pharmaceuticals grant. A randomized, double-blind trial of Telbivudine vs.Llamivudine in Adults with Compensated Chronic Hepatitis B. Grant award: $106,427.

2002 2009Sub-Investigator: XTL Pharmaceuticals grant. A pilot phase II, multi-center, randomized, double-blind, placebo-controlled, dose escalation Study of the Safety and Efficacy of Human HCV-antibody (HCV-AB 68) for Prevention of Hepatitis C Disease Recurrence in Patients who have Received Hepatic Allografts for Treatment of End-stage Liver Disease due to Hepatitis C Virus Infection. Grant award: $10,000.

2003 2004Principle Investigator: Bristol-Meyers Squibb. Entecavir vs. Lamivudine (52 weeks therapy) in Adult patients with Chronic Hepatitis B who have had an Incomplete Response to Lamivudine Therapy: Rollover study.

2003Sub-investigator: Medtronic grant. Interstim sacral nerve stimulation therapy for bowel control: Fecal incontinence study.

2003Principle Investigator: Roche Pharmaceuticals grant. Randomized, open-label study of Pegasys and Epivir-HBV as initial treatment of HBeAg negative HBV.

2003 Sub-investigator: Two-week randomized, double-blind, placebo-controlled study of PRN, BID and fixed dosing regimens of alosetron in female subjects with severe diarrhea-predominant irritable bowel syndrome who have failed conventional therapy.

2003 Principle Investigator: Idun Pharmaceuticals grant. Caspase study for the treatment of chronic liver disease including chronic HCV infection.

2003 Principle Investigator: United Therapeutics grant. Phase II study of UT 231, including PK assessment, in patients with chronic HCV who were non-responders to previous interferon and ribavirin therapy.

2003 Principle Investigator: Actelion Pharmaceuticals. Phase II Study of tezosentan for the treatment of portal hypertension.

2003SubInvestigator: Celera grant. Natural history of fibrosis in patients who had undergone treatment for HCV.

2003 2004Principle Investigator: Chiron grant. Evaluation of the Procleix HIV-1/HCV RNA qualitative assay in detecting HCV RNA from whole blood from HCV infected patients.

2003 2006Sub-Investigator: Hoffman-LaRoche grant. Rrandomized, multi-center, open-label, phase IV study evaluating efficacy and safety of 16 week vs. 24 week treatment with Pegasys in combination with Copegus in interferon-nave patients with chronic hepatitis C genotype 2 or 3 virus infection. Grant award: $136,513.

2003 2006Principle Investigator: Gilead Pharmaceuticals grant. Long-term study of durability of seroconversion in patients with chronic hepatitis B virus infection who have seroconverted while participating in the previous Gilead-sponsored study of adefovir dipivoxil. Grant award: $1,000.

2003 2005Principle Investigator: Celera grant. DNA genotyping and mRNA profiling of newly recruited, treatment-nave HCV patients. Grant award: $120,300.

2003 2004Principle Investigator: XTL Pharmaceuticals grant. Phase II, multi-center, randomized, open-label, dose ranging, parallel group study of the antiviral effects, pharmacokinetics and safety of HepeX-B as compared to hepatitis B immune globulin in patients who have received hepatic allografts for hepatitis B virus infection. Grant award: $7,400.

2004 Principle investigator (CPMC): Amgen grant. Treatment of ribavirin-induced anemia during the treatment of chronic HCV with darbopoietin (ADHERENCE trial).

2004Principle investigator: (CPMC) Ortho Biotech grant. Prospective treatment trial using erythropoietin to treat anemia due to ribavirin during interferon treatment for chronic HCV infection.

2004Principle Investigator: Eximias Pharmaceutical Corp. grant. Phase III Evaluation of THYMITAQ(R) nolatrexed dihydrochloride, in unresectable hepatocellular carcinoma (ETHECC[C]) trial.

2004Co-Principle Investigator: WEAVE (WEST EAST ANTIVIRAL EFFICACY) protocol- Randomized trial of Pegasys/ribavirin vs. Pegasys/ribavirin and CAM therapy.

2004 2005Principle Investigator: Idun Pharmaceuticals grant. A phase III dose-response study of caspase inhibitor in hepatitis C patients. Grant award: $62,100.

2004 2005Sub-Investigator: Boehringer Ingleheim grant. A pharmacokinetic study to assess nevirapine levels in HIV-infected patients with impaired hepatic function. Grant award: $19,929.

2004 2006Sub-Principle Investigator: Ortho Biotech grant. Procrit for the treatment of post-transplant anemia. Grant award: $50,000.

2004 2006Principle Investigator: eXagen Diagnostics grant. Identification of a molecular signature from peripheral blood that predicts interferon response in hepatitis C infection. Grant award: $30,000.

2004 2006Sub-Investigator: Hoffman-LaRoche grant. Prospective, randomized, multi-center, open-label, comparative safety and efficacy study of prophylactically administered pegylated interferon plus ribavirin vs. no prophylaxis following liver transplantation for hepatitis C. Grant award: $246,608.

2004 2007Principle Investigator: Valeant Pharmaceuticals grant. Phase II randomized, double-blind, multi-center study to compare safety and efficacy of viramidine to ribarivin in treatment-nave patients with chronic hepatitis C. Grant award: $202,395.

2004 2007Sub-Investigator: Vertex Pharmaceuticals grant. Phase 2b study of merimepodib in combination with interferon and ribavirin in subjects with chronic hepatitis C genotype 1 non-responsive to prior therapy and interferon. Grant award: $96,740.

2004 2009Co-Investigator: NIH grant. Early detection of liver cancer. Grant award: $50,694. 2005 2007Principle Investigator: Stanford University grant. CPMC/Stanford keratin study of liver disease in African Americans. Grant award: $2,000.

2005 2007Sub-Investigator: Idenix Pharmaceuticals grant. A randomized, double blind trial of telbivudine vs. adefovir dipivoxil in adults with HBeAg-positive, compensated chronic hepatitis B. Grant award: $28,380.

Curriculum VitaeROBERT G. GISH, M.D.29

RESEARCH SUPPORT: Continued

2005 2008Sub-Investigator: Idenix Pharmaceuticals grant. Open-label study of telbivudine in adults with chronic hepatitis B previously treated in Idenix-sponsored telbivudine studies. Grant award: $126,005.

2005 2007Sub-Investigator: Idenix Pharmaceuticals grant. Randomized, phase IIb clinical trial to evaluate the safety and antiviral activity of NM283 and the combination of interferon plus NM283 in patients with chronic hepatitis C who have previously failed to respond to standard therapy. Grant award: $69,883.

2005Sub-Investigator: Hemolife Medical grant. Continuous plasma filtration with sorbent adsorbent detoxification utilizing the HemoLife Medical Inc. HLM 100 column and the HLM-200 plasma filter for the treatment of episodic type C hepatic encephalopathy in subjects with decompensated cirrhosis. Grant award: $86,790.

2005Sub-Investigator: Orphan Therapeutics grant. A double-blind, randomized, placebo-controlled, multi-center phase III study of intravenous terlipressin in patients with hepatorenal syndrome Type 1. Grant award: $34,791.

2007 2008Principle investigator: Nucleonics siRNA therapy for the treatment of chronic hepatitis B. Grant award: $124,000.

2008 2010PROTOCOL GS-US-174-0108 A Phase II, Double-Blind, Multi-Center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir In The Treatment Of Chronic Hepatitis B Subjects With Decompensated Liver Disease And In The Prevention Of Hepatitis B Recurrence Post-Transplantation. Budget $26,642

2010 Sub-Investigator: Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection.

2010 Sub-Investigator: Ph 2 rollover protocol of Telaprevir (VX-950) in combination with Peginterferon Alfa-2a and Ribavirin in subjects enrolled in the controlled group (Group A) of study VX06-950-106, VX05-950-104 and VX05-650-104EU who did not achieve or maintain an undetectable HCV RNA level through sustained viral response.

2010Sub-Investigator: A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients with BK Virus Nephropathy (CASG209).

2010Sub-Investigator: Multicenter, randomized, double-blind, placebo controlled, multiple dose study of the safety, tolerability and population pharmacokinetics of CMX001 in post transplant subjects with BK virus viruria.2010Sub-Investigator: A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation.

2010Sub-Investigator: A Phase II randomized, double-blind, placebo-controlled study of Sorafenib or Placebo in combination with transarterial chemoembolization (TACE) performed with DC bead and doxorubicin for intermediate stage hepatocellular carcimoma (HCC).

2010Principle-Investigator: A Randomized, Double-blind, Multi-center Phase II Study of Brivanib plus Best Supportive Care (BCD) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib. Budget amount $244,105.00

2010Sub-Investigator: A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination with Sorafenib (Nexavar) in Patients with Advanced or Metastic Hepatocellular Carcinoma (HCC).

2010Sub-Investigator: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib.

2010Principle-Investigator: Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administed in Combination with Ribavirin to Treatment-Nave Subjects with Chronic Hepatitis C Virus Infection. Budget $48,950.00

2010Sub-Investigator: A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study.

2010Principle-Investigator: A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated with Adefovir Dipiivoxil for Chronic Hepatitis B and having Persistent Viral Replication.

2010Sub-Investigator: An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies. NV-02B-022.

2010Sub-Investigator: A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-TACRO Tablets Once Daily and Program Capsules Twice Daily in Adult De Novo Liver Transplant Patients.

2010Sub-Investigator: A Phase 2, Randomized, Double-Blind, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment Nave Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.

2010Sub-Investigator: Salix Pharmaceuticals, Inc./A Multi-Center, Open-Label, Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 BID in Subjects with a History of Hepatic Encephalopathy.

2010Sub-Investigator: Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis C.

2010Sub-Investigator: Ph2, Open label randomized study to evaluate the efficacy and safety of the combination product, Emtricitabine/Tenofovir (Truvada) in the presence of absence of Hepatitis B immunoglobulin (CHB) post-orthotopic liver transplant (OLT).

2010Sub-Investigator: An open-level, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C216 trail who failed therapy for virologic reasons. 2010Sub-Investigator: Phase III, 24 dose regimens of Telaprevir in combination with Peginterferon alfa 2a and Ribavirin in treatment nave subjects with genotype 1 chronic hepatitis C.

2010Sub-Investigator: Randomized study of stopping treatment at 24wks vs. continuing treatment to 48 weeks in treatment-nave subjects with Genotype 1 CHC who achieve an extended RVR while receiving Telaprevir, Peginterferon (Peasys) and Ribavirin (Copegus).

2010Sub-Investigator: A 3-Year, Virology Follow up Study in Subjects Previously Treated WithTelaprevir in Select Clinical Studies.

2010Sub-Investigator: Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects with Fulminant Hepatic Failure (FHF).

2010Sub-Investigator: Efficacy and Safety of the Extravorporeal Liver Assist Device (ELAD) in Subjects with Acute on Chronic Hepatitis (AOCH).

2010Sub-Investigator: A multi-center randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety and tolerability of Rifaximin 550 mg bid for 6 months in preventing hepatic encephalopaty.

2010 ILCS Horizon Scanning Protocol International and National Priorities for Liver Cancer Control. Johns Hopkins Bloomberg School of Public Health IRB.

4/2010 8/2013Co-Primary Investigator: NV20536. A Roche Study: A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. Grant Award: $214,336.60.

11/2010 8/2013Co-Primary Investigator: NV22688. A Roche Study: A Long-Term Monitoring Study To Evaluate The Persistence Of Direct Acting Antiviral (DAA) Treatment-Resistant Mutations Or The Durability Of Sustained Virological Response (SVR) In Patients Treated With DAA-Containing Regimens For Chronic Hepatitis C Infection (CHC). Grant Award: $21,273.00.

4/2011 8/2013Co-Primary Investigator: P7977-0724. A Gilead Sciences & Pharmasett study: A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of PSI-7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Nave Patients with Chronic HCV Infection Genotype 1,4,5, or 6. Grant Award: $117,872.

2011 Co-Primary Investigator: WV21913C. A Roche Study: A Randomized, Open-Label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (DNV/r) and Copegus, in Combination with the HCV Polymerase Inhibitor Prodrug RO 5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients who have Failed a Previous Course of Peginterferon Alfa Plus Ribavirin Combination Therapy. Grant Award: $141,986.

6/2011 8/2013Co-Primary Investigator: GS-US-248-0120. A Gilead Sciences, Inc. Study: A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection. Grant Award: $213,102.

9/2011 8/2013Co-Primary Investigator: GS-US-248-0121. A Gilead Sciences, Inc. Study: A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 with Peginterferon Alfa 2a (PEG) and Ribavirin (RBV) in Treatment-Nave Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype. Grant Award: $59,742.

2011 8/2013Primary Investigator: BIPI 1220.48. A Boehringer Ingelheim Study: A Phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-a (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment [Version 3.0] Grant Award: $89,739.

2011 8/2013Co-Primary Investigator: AI444038. A Bristol-Myers Squibb Study: Open-Label, Single Arm Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection. Grant Award: $92,572.

2011 8/2013Co-Primary Investigator: GS-US-248-0123. A Gilead Sciences, Inc. Study: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection. Grant Award: $33,491.

2011 8/2013Co-Primary Investigator: GS-US-248-0122 . A Gilead Sciences, Inc. Study: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection. Grant Award: $33,491.

2011 8/2013Co-Primary Investigator: NV27779. A Roche Study: A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study To Evaluate The Sustained Virologic Response Of The HCV Polymerase Inhibitor Prodrug Ro5024048 In Combination With Telaprevir And Pegasys/Copegus In Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders To Treatment With Pegylated Interferon/Ribavirin. Grant Award: $95,089.

2011 8/2013Primary Investigator: P2938-0721. A Gilead Sciences / Pharmasett, Inc. Study: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients with Chronic HCV Infection. Grant Award: $273,564.

2012 8/2013Primary Investigator: BMS AI444-043. A Brstol-Myers Squib Study: A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg- Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV). Grant Award: $73,976.

2012 8/2013Co-Primary Investigator: VX11-950-114. A Vertex Study: A Phase 3b Study of 2 Treatment Durations of Telaprevir, PEG-INF (Pegasys), and Ribavirin (Copegus) in Treatment-Naive and Prior Relapser Subjects with Genotype 1 Chronic Hepatitis C and IL28B CC Genotype [Version 2.0]. Grant Award: $58,092.

2012 8/2013Co-Primary Investigator: P7977-2025. A Gilead Sciences / Pharmasett, Inc. Study: An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant. Grant Award: $80,722.

2012 8/2013Co-Primary Investigator: GS-US-334-0107 . A Gilead Sciences, Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon. Grant Award: $102,037.

2012 8/2013Co-Primary Investigator: GS-US-334-0109, A Gilead Sciences, Inc. Study: An Open-Label Study of GS-7977+ Ribavirin with or without Peginterferon Alfa-2a in Subjects with Chronic HCV Infection who Participated in Prior Gilead HCV Studies Grant Award: $94,440.

2012 8/2013Co-Primary Investigator: GS-US-334-0108, A Gilead Sciences, Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection. Grant Award: $100,831.

2012 8/2013Primary Investigator: P7977-1231, A Gilead Sciences / Pharmasett, Inc. Study: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Nave Patients with Chronic Genotype 2 or 3 HCV Infection. Grant Award: $43,041.

2012 8/2013Primary Investigator: GS-US-283-0102, A Gilead Sciences, Inc. Study: A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging, Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects with Chronic Hepatitis B Virus Infection. Grant Award: $43,041.

2012Primary Investigator: GS-US-283-0106, A Gilead Sciences, Inc. Study: A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects with Chronic Hepatitis B Virus Infection. Grant Award: $178,385. 6/1/12 8/2013.

2012Primary Investigator: GS-US-243-0102., A Gilead Sciences, Inc. Study: A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Nave Subjects with Chronic Hepatitis C Virus Infection. Grant Award: $183,441. 6/1/12 8/2013.

2012Primary Investigator: GS-US-283-0110, A Gilead Sciences, Inc. Study: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Loss of S Antigen (HBsAg) and Sustained HBV Viral Load Reduction Below the Limit of Quantitation (BLQ) in Gilead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepatitis B Infection. Grant Award: $139,400. 7/1/12 8/2013.

2012Co-Primary Investigator: GS-US-334-0110, A Gilead Sciences, Inc. Study: A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 with Peginterferon Alfa2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection. Grant Award: $102,411. 7/1/12 8/2013.

2013Co-Primary Investigator: GS-US-337-0109, A Gilead Sciences, Inc. Study: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection. Gilead Sciences, Inc. Grant Award: $116,799. 1/1/13 8/2013.

2013Co-Primary Investigator: GS M14-002. An AbbVie Study: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Nave Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV). Grant Award: $126,539.00. 3/1/13 8/2013.

2013Co-Primary Investigator: GS-US-337-0108, A Gilead Sciences, Inc. Study: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir / Ledipasvir Fixed-Dose Combination Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Nave Subjects with Chronic Genotype 1 HCV Infection. Grant Award: $104,650. 5/1/13 8/2013.

Curriculum VitaeROBERT G. GISH, M.D.31

RESEARCH SUPPORT: Continued

2013GS-US-342-0102, A Gilead Sciences, Inc. Study: A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Nave Subjects with Chronic HCV Infection . Grant Award: $46,551. 5/1/13 8/2013.

Curriculum VitaeROBERT G. GISH, M.D.28

UCSD: RESEARCH / ADVISORY

2012 Co-Principal Investigator: Biological Markers and Outcomes in Hepatitis C and Other Liver Diseases. All UCSD Health Systems. Other Co-Principal Investigator: Julio Gutierrez, MD.

2013 Co-Principal Investigator: STOPC Biobank Genetics Consortium (UCSD Unit). Other Co-Principal Investigator: Alexander Kuo, MD.

2012Principal Investigator: Retrospective Analysis of UCSD Liver Patient Population, UCSD Medical Center, 5-Year Study. UCSD Liver Center.

2011Principal Investigator: POC Hepatitis B and Hepatitis C: Screening for Viral Hepatitis, Its Role in Linkage to Care and Economic Ramification in Healthcare, Asian Pacific Health Foundation (APHF) Community Outreach Events. In Process.

2011Principal Investigator: Retrospective Analysis of UCSD Liver Patient Population. UCSD Human Research Protections Program. UCSD Medical Center. Study is for 5 years, In Process.

2011 2013 Principal Investigator: UCSD Liver Research Biorepository.UCSD Health Systems.

2012Principal Investigator: An International Multi-Center, Blinded, Randomized Study to Investigate Safety, Tolerability, PK and PD Following Administration of Regimens Containing PSI-352938, PSE-7977, and Ribavirin in Patients with Chronic HCV, AVRC at UCSD.

2012 2013Principal Investigator: Barriers to Hepatitis B Screening and Hepatitis B Knowledge Among Asian Population in San Diego County. All UCSD Health Systems.

2012 2013 Study to Improve Early Identification of Hepatitis B (HBV) and C (HCV) Infections in Clinical and Community Settings and to Enhance Linkage to Care, Treatment, and Preventive Services for Infected Persons. Grant submitted by Hepatitis Free San Diego in collaboration with the Antiviral Research Center, University of California, San Diego. Approved by Centers for Disease Control and Prevention (CDC), September 2012 for 1 year.

2013 PresentCo-investigator: A University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences study; Cost-Effectiveness of Hepatitis C Screening: Point of Care (POC) vs. Standard of Care Tests.Curriculum VitaeROBERT G. GISH, M.D.36

UCSD: RESEARCH / ADVISORY: Continued

2012 PresentCo-investigator: A University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences study. Cost Efficiency Analysis of Point-of-Care versus Standard of Care Tests for Hepatitis B in Asian Americans in San Diego County.

8/31/2013 Robert G. Gish MDPresentRobert G. Gish Consultants, LLCBusiness address: 6022 La Jolla Mesa DriveSan Diego, CA 92037Cell phone: 1 858 229 9865Email: rgish@robertgish.comWebsite: robertgish.com

COINVESTIGATOR: GASTROINTESTINAL TRIALS

2002Tegaserod vs. Placebo, for functional dyspepsia with documented delayed gastric emptying. (Novartis).

2002A phase III, double-blind, multicenter, randomized, placebo-controlled study of the effects of a somatostatin analogue - lanreotide as an adjuvant to endoscopic band ligation of patients with acute bleeding from oesophageal varies secondary to cirrhosis and portal hypertension (Biomeasure).

2002Performance evaluation of the given diagnostic imaging system in the upper gastrointestinal tract (given imaging).

2002An efficacy and safety study of intravenous pantoprazole in the prevention of recurrent peptic ulcer bleeding after successful hemostasis (Wyeth-Ayerst).

2002Prospective comparison of air contrast barium enema (ACBE) computed tomographic colonography (virtual colonoscopy) and colonoscopy for evaluation of the colon.

2002Evaluation of investigational sclerotherapy-type needle for tissue identification (Enterics).

2002A pilot Phase II, muliticenter, randomized, double-blind, placebo-controlled, dose escalation study of the safety and efficacy of human HCV-antibody (HCV-Ab XTL 68) for prevention of hepatitis C disease recurrence in patients who have received hepatic allografts for treatment of end-stage liver disease due to hepatitis C virus infection.

2010Moving towards comprehensive liver cancer control: A qualitative study.

2010Applying conjoint analysis to develop a comprehensive liver cancer control plan in Asia.

2011Predicting the future impact of emerging technologies on Hepatocellular carcinoma (HCC): Measuring stakeholders preferences with best-worst scaling.

2011Stakeholder involvement in priority setting of strategies to improve hepatocellular carcinoma policy (EU data).

2011Predicting the future impact of emerging technologies on Hepatocellular carcinoma (HCC): Measuring stakeholders preferences with best-worst scaling.

2011Predicting the future impact of emerging technologies on hepatocellular carcinoma (HCC): Using best-worst scaling to explore clinicians views.

2011Controlling liver cancer internationally: A qualitative study of clinicians perceptions of current public policy needs.

2011Stakeholder involvement in priority setting of strategies to improve liver cancer control policy in Asia.

2011Focus will be all Asian data results vs. USA - performance needs and discussion around country-level differences (possible publication in special supplement of ONCOLOGY, tbc).

2011 Evaluation of the Merits of the Evidence Regarding the Identification of Hepatitis C Virus (HCV) and HCV-Related Chronic Disease Among Persons Born from 1945 to 1965.

2012 Associate Member, Moores UCSD Cancer Center.

2013Editorial Advisory Board, Gastroenterology & Hepatology Journal, Digestive Disease Week Breakfast, Orlando, FL.; May 19, 2013.

Curriculum VitaeROBERT G. GISH, M.D.34

COINVESTIGATOR: GASTROINTESTINAL TRIALS: Continued

2011 2013STOPSC Genetics Recruitment; Studies of Primary Sclerosing Cholangitis (STOPSC) is a multi-center joining effort to understand the possible causes and treatment of Primary Slerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) as well as the effects of the disease on the liver over timeTEACHING ACTIVITIES

19871988Consult AttendingGastroenterology and Liver ServicesWadsworth Veterans HospitalLos Angeles, California

19871988Clinical ToxicologyUCLA School of MedicineLos Angeles, California

19891991UC Davis Liver ConferenceMartinez VA, University of California, DavisMartinez, California

19911995Gastroenterology and Liver ClinicUniversity of California, DavisSacramento, California

1994Visiting ProfessorUniversity of FloridaGainesville, Florida

1996Visiting ProfessorUniversity of IowaIowa

1996, 1997 & 2003Visiting ProfessorUniversity of California, Los AngelesLos Angeles, CA

2003Visiting ProfessorUniversity of ColoradoDenver, Colorado

2006Visiting ProfessorUniversity of Southern California Los Angeles, California1988 2010Gastroenterology Teaching ServiceHighland General Hospital, Alameda County Medical CenterOakland, California

1988 2010Gastroenterology and Liver Teaching ServiceCalifornia Pacific Medical CenterSan Francisco, California

1993 1999Merced Community HospitalTeaching FacultyFamily Medicine ProgramMerced, CaliforniaUniversity of California, DavisSacramento, CaliforniaCurriculum VitaeROBERT G. GISH, M.D.35

COMMITTEES

TEACHING ACTIVITIES: Continued

1996 2010Department of MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaOSCE 1995-2002Medicine Teaching Service at CPMCHousestaff Teaching Service at Highland Hospital50 hours per year of teaching service (minimum)

2008 2010Department of MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaMedicine Teaching Service(a total of 88 hours of preceptorship)

2010 2013 Department of Medicine University of California, San Diego San Diego, California

2013Consultant to Hepatitis Free San Diego Elective Course, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California

2013Developed and Funded New Graduate Training Program Committee approval for Transplant Hepatology fellow for one year, Dr. Heather Patton, Department of Medicine, University of California, San DiegoSan Diego, California

June 2013Review of Dr. Tami Daugherty for Clinical Associate ProfessorDepartment of Medicine, Stanford University School of Medicine,Division of Gastroenterology and HepatologyStanford, California

COMMITTEES

1989 1992Member, Human Liver Cell Culture FacilitySRI InternationalMenlo Park, California

1989 1992Member, Executive CommitteePacific Transplant InstituteSan Francisco, California

1990 1992Executive Vice President, S.F. Bay Area ChapterAmerican Liver FoundationCurriculum VitaeROBERT G. GISH, M.D.41

COMMITTEES: Continued

San Francisco, California

1990 1992Chairman, Fundraising CommitteeS.F. Bay Area ChapterAmerican Liver FoundationSan Francisco, California

1991 1993Member, Scientific Exhibits CommitteeAmerican Society for Gastrointestinal Endoscopy

1992 1993Chairman, Nominating committee S.F. Bay Area ChapterAmerican Liver FoundationSan Francisco, California

1992 1993Chairman, Public Education Committee S.F. Bay Area ChapterAmerican Liver FoundationSan Francisco, California

1993Member, Committee for Test Question Development American Board of Internal Medicine1993 1996Chairman, Medical Advisory CommitteeS.F. Bay Area ChapterAmerican Liver FoundationSan Francisco, California

1994 1997 Member, Committee on Liver and Intra-abdominal Organ TransplantationAmerican Society of Transplant Physicians

1996Member, Abstract Review CommitteeAmerican Society of Transplant Physicians

1997 1998Member, Hepatitis Task ForceState of California Public Awareness and Department of Corrections, under direction of Senator Polanco

1997 2001Member, Clinical Research CommitteeAmerican Association for the Study of Liver Diseases 1999SecretaryHepatitis Resource Network

1999 2000Chairman, Search CommitteeCalifornia Pacific Medical Center Pathologist San Francisco, CA

1999 2013Member, Governing Council Abstract ReviewerAmerican Association for the Study of Liver Diseases (AASLD)

1999 2001Co-Chair, Membership CommitteeAmerican Society of Transplantation

2001 2002Medical Adivsory CommitteeAmerican Liver FoundationSan Francisco, California

2001 2002Member, HCV Advocate Medical Writers Circle

2002 2004Member, Abstract Review CommitteeAASLD

2003ChairAASLD Topic Forum

2003Faculty MemberAASLD Expert Consensus Conference

2003Task Force MemberSanta Barbara County HCV Strategic Plan

2003 2006Member, Liver and Intestinal Transplantation CommitteeOrgan Procurement and Transplantation Network (OPTN)/UNOS

2004Member, Health Liver Alert Screening CommitteeAmerican Liver Foundation

2004Expert Council Member Advancing Clinical Treatment of Hepatitis B Virus (ACT-HBV) Initiative

2004 2006Member, Fund Development CommitteeAASLD

2005 2007Member, Public Policy CommitteeAASLD

2004 2010Member, Research Development Committee California Pacific Medical Center2006 PresentMember, Scientific CommitteeHep Dart Conference

1994 2007Director, Department of Transplantation Serum and Tissue BankCalifornia Pacific Medical Center

1995 2007Liver Center MemberUniversity of California, San Francisco

1996 1998Member, National Scientific Review CommitteeAmerican Liver Foundation 1997 2000Member, Membership CommitteeAmerican Society of Transplant Physicians1997 2003Medical Review SubcommitteeAmerican Liver Foundation1997Member, Southern China Hepatitis Study GroupGuangzhou, China and Hong Kong

1998 2010Member, Committee on Information Technology California Pacific Medical Center San Francisco, California

2004 2005Member, Hepatitis Plan WorkgroupState of Nevada

2007Member, Fund Raising Study Task ForceAASLD

2007Abstract ReviewerAmerican Transplant Congress

2007 2008Member, Organizing CommitteeHong Kong-Shanghai International Liver Congress

2007 2010San Francisco Hep B Free Campaign

2008 2010Board Member, American Liver Foundation, San Francisco Chapter

2008 2010Advisor, LASHLocal Area Support for Hepatitis, Inc. (L.A.S.H.)

2008 PresentBoard Member, FAIR Foundation

2008 PresentScientific Advisory Committee, Global Antiviral Journal

2009 Program of comprehensive research actions: Hepatocellular carcinoma. French National Cancer Institute. Grant Review. 2009 2009 2010Member at large, Nominating CommitteeAmerican Society of Transplantation (AST)

2009 PresentBoard MemberHepatitis C Oversight Partnership (HepCop)

2009 Present Group Membership, AASLD Special Interest Group on Hepatitis B (SIG)

2010 PresentScientific Board MemberAsian Pacific Association for the Study of Liver Disease (APASL)

2010Abstract ReviewerAsian Pacific Association for the Study of Liver Disease (ASPASL), Beijing, China

2009 2013Co-Chair of and Memberof Steering CommitteeAASLD Hepatitis B Special Interest Group (SIG)

2010Nomination CommitteeSan Francisco Medical Society

2010 PresentMember, Hepatitis D International Network

2011 PresentLI-RADS (Liver Imaging Reporting and Data System)

2011 Abstract review panel: AASLD Fall meeting

2011 PresentSan Diego County Medical Society

2011 PresentMember, Philippines Viral Hepatitis Project

2012 2013Graduate Medical Education Enrollment Committee, Transplant Hepatology Program University of California, San Diego.

2012 PresentMember, International Coalition of Hepatology Educators

2012Abstract Review Committee, American Association for the Study of Liver Disease

2012 2013Vice President, Steering committee of the National Viral Hepatitis Round Table

2012 2015Member,National Viral Hepatitis Round Table

2012 PresentMember, Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP)

2011 & 2012Faculty Interviewer Committee, Internal Medicine Residency Applicants, University of California, San Diego Department of Internal Medicine.

2013AASLD Abstract Review Committee

2013Member, Editorial Advisory Board, Gastroenterology & Hepatology Journal, Digestive Disease Week Breakfast, Orlando, FL., May 19, 2013.

2011 2013EMR Provider Optimization Group (POG) EPIC Commitee

2013 Planning and Steering Committee Member for Imaging and Surveillance, Liver Cancer Roundtable

2013 Executive Vice-Chair, National Viral Hepatitis Roundtable Committee

2013 PresentFounding Member, Liver Cancer Roundtable

2010 Co-Chair, the 2nd Biannual International Conference of Armenian Hepatological Forum.

2013Finance Review Committee, American Association for the Study of Liver Diseases (AASLD), Annual Business Meeting

2014Committee Member Nominee, Centers for Disease Control and Prevention (CDC)/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT).

2014 PresentMedical DirectorHepatitis B Foundation, Doylestown, PA

2014 PresentMemberCurriculum VitaeROBERT G. GISH, M.D.40

COMMITTEES: Continued

Curriculum VitaeROBERT G. GISH, M.D.41

COMMITTEES: Continued

Global Hepatitis Community, www.hepcomm.com

1999 2002Member, Medical Advisory BoardSchering-Plough InforMed Hepatology

1999 2002Cheng Si Yaun, Hong Kong and Beijing, Research and Education in Liver Disease, Board Member, Peoples Republic of China

2001 2003Member, Data Safety Monitoring BoardDepartment of Health and Human Services, National Institutes of Health Civacir HCV immunoglobulin protocol

2002 2010Chair, U.S. Hepatitis B Advisory BoardBristol-Meyers Squibb Corporation

2002 2006At-large Member, Region 5Organ Allocation Listing CommitteeRegional Review BoardUnited Network for Organ Sharing (UNOS)

2003 2004Member, Data Safety Monitoring BoardCivicir Research protocol to prevent recurrent HCV after liver transplantation

1999 PresentBoard Member, Hepatitis C Caring Ambassadors

2007Editorial Board, Antiviral Therapy Manuscript Central

2003 2006Member, Advisory BoardLiver Institute for Education and Research (L.I.F.E.R.) Foundation

2004 PresentMember, Editorial Board Liver Transplantation

2005 PresentMember, Editorial Advisory BoardGastroenterology & Hepatology

2007 Present Hepatitis B Foundation Medical and Scientific Advisory

2009 PresentMember, Board of DirectorsHepaHope

2009Member, International Advisory BoardEgyptian Society of Liver Cancer (ESLC)

2011Member, Advisory Board, PharmassetCurriculum VitaeROBERT G. GISH, M.D.42

BOARD ACTIVITIES

1992Member, Academic Review Board University of Florida Gainesville, Florida

1992 1994Member, Advisory BoardHepatitis B Demonstration Project City of San Francisco, Children's ImmunizationSan Francisco, California

1999 2002Medical Director, Board of DirectorsHCV Global Foundation

1999 2000 Editorial BoardCurriculum VitaeROBERT G. GISH, M.D.43

BOARD ACTIVITIES: Continued

Curriculum VitaeROBERT G. GISH, M.D.42

COMMITTEES: Continued

The Practical Hepatitis Newsletter (PHN)

2011 PresentMember, Philippines Viral Hepatitis Project

2011Southern Nevada Health District (SNHD)21st Holoaulea Festival (Pure Aloha Festival). (September 2011) hosted by Las Vegas Hawaiian Civic Club Leadership

2012 PresentMember, Liver Imaging Radiology Committee (LI-RADS) University of California, San Diego.

2012 PresentMember, Abstract Review CommitteeAmerican Transplant Congress (ATC), Review Program Live.

2012At Large, Board NominationsNominee, American Association for the Study of Liver Diseases,Governing Board, May 2012.

2013At Large, Nominee, American Association for the Study of LiverDiseases, Governing Board, and Treasurer, May 2013.

2013 PresentNational Hepatitis B Task Force, Advisory Board.

2013 Present Advisory Board MemberNorth American Journal of Medicine and Science (NAJMS).

2013 PresentMember, Gastroenterology & Hepatology Editorial Advisory Board.

2013 PresentAdvisor, National Viral Hepatitis Task Force (NVHTF)

2013 PresentAdvisor, Viral Hepatitis Foundation (VHF)

2013 PresentAdvisor, Hepatology Society of the Philippines

2013Advisor, Abstract Review Committee, American Association for the Study of Liver Disease Annual Conference Committee, Washington, D.C., November 1-5, 2013

2013Advisory Board Member, Tan Tao School of Medicine, Ho Chi Minh City, Vietnam

2013Academic Peer Review Surakit Pungpapong, M.D., Associate Professor of Medicine, College of Medicine, Mayo Clinic, October 8, 2013.

2014 2015Member, Drug Safety Monitoring Board, Isis PharmaceuticalsHBV Phase 2 Drug Development

Curriculum VitaeROBERT G. GISH, M.D.44

BOARD ACTIVITIES: Continued

EDITORIAL ACTIVITIES

Alimentary Pharmacology & TherapeuticsArchives of Medical ResearchASTP Abstract Review CommitteeAmerican Journal of GastroenterologyBiodrugsDiabetes CareDigestive Diseases and SciencesEuropean Journal of Gastroenterology & HepatologyGastroenterologyGastrointestinal EndoscopyGutHepatologyJournal of Clinical InvestigationJournal of Gastrointestinal EndoscopyJournal of HepatologyJournal of Infectious DiseaseLiver Transplantation and SurgeryLiver InternationalMayo Clinic ProceedingsObstetrics and GynecologyTransplantation ProceedingsTransplantationJournal of AIDSSection Editor, Current Hepatitis Reports, Vol. 1, No. 1, November 2007Peer View/in FocusGastroenterology Clinics of North AmericaJournal of Virology Review 2005 EditionEuropean Journal of Gastroenterology & Hepatology

Associate Editor:Chinese Hepatology 2005

Thesis Advisor: PhD in PsychologyLouise I. Bertman, 1999Compliance, noncompliance and comparative MMPI-2 profiles of alcohol-dependent and non-alcohol-dependent patients evaluated for orthotopic liver transplantation

Curriculum VitaeROBERT G. GISH, M.D.46

MENTEE LIST

NAME ETHNICITYMENTOR RELATIONSHIP POSITION NOW(Dates, How mentored)

Debbie Hana-YiKorean2008-2010 research associateNYU Residency

Michael MangahasFilipino2008-2010 research associateMed student; UCSF/UC Berkeley

Sumbella F. Baqai, MDPakistani2008-2010 research associateResident and Chief ResidentDepartment of Internal Medicine; Alameda County Medical Center, Oakland, CA

Javaheri ShahramPersian1999-2000: GI FellowFellowship mentor

Aris MendiolaPilipino2000-2001: GI FellowFellowship mentor

Sheila SavurIndonesian2001-2001: GI FellowFellowship mentor

Tammy DaughertyCaucasian2000-2003: GI FellowFellowship mentor

Linda NguyenVietnamese2000-2003: GI FellowFellowship mentor

Daniel RengstorffCaucasian2001-2004: GI FellowFellowship mentor

Ann ChenChinese2003-2004: GI FellowFellowship mentor

Christine PizzuteCaucasian2004-2005: GI FellowFellowship mentor

Jessie LiuChinese2005-2006: GI FellowFellowship mentor

Katerina ShetlerRussian/Ukrainian2005-2006: GI FellowFellowship mentor

Mimi LinChinese2006-2007: GI FellowFellowship mentor

Liz ClarkChinese/Hawaiian2007-2008: GI FellowFellowship mentor

Michele TanaChinese2008-2009: GI FellowFellowship mentor

Cathy CabansagFilapina2008-2009: GI FellowFellowship mentor

Edward HoltCaucasian2009-2010: GI FellowFellowship mentor

Irene VodkinCaucasian2007-2008: Preceptor for students Longitudinal Clinical Experience (LCE)UCSF Med Student

Iris MaChinese2008-2009: Preceptor for students Longitudinal Clinical Experience (LCE)UCSF Med Student

Arlene VazquezHispanic2009-1010: Preceptor for students Longitudinal Clinical Experience (LCE)UCSF Med Student

Patricia ZhengChinese2010-2011: Preceptor for students Longitudinal Clinical Experience (LCE)UCSF Med Student

Steve KaneCaucasian2010-2013Premed student, research associate

Margaret ClarkCaucasian2010-2013Premed student, research associate

Erica BoettcherCaucasian2010 2013GI Fellow

Brigid BolandCaucasian2010 2013GI Fellow

Imad ElkhatibMiddle Eastern2010 2013GI Fellow

Wilson KwongAsian2011 2013GI Fellow

Michael McTigueCaucasian2011 2013GI Fellow

Mazen NourredinCaucasian2010 2013GI Fellow

Suresh PolaAsian Indian2010 2013GI Fellow

Ashish ShahAsian Indian2011 2013GI Fellow

Amir ZarrinparPersian2011 2013GI Fellow

Ingrid GonzalezHispanic2011 2013GI Fellow

Thuy Anh LeAsian2010 2013GI Fellow

Julio GuttierrezHispanic2010 2013GI Fellow

Fred ParkAsian2011 2013GI Fellow

Curriculum VitaeROBERT G. GISH, M.D.48

MENTEE LIST: Continued

NAME ETHNICITYMENTOR RELATIONSHIP POSITION NOW(Dates, How mentored)

Toritsesan Boyo (Tosan)Nigerian2011-2013Business Resident

Lilly NguyenVietnamese2013 2013Pharmacy Student

Thuy NguyenVietnamese2013 Pharmacy Student

Xuan PhanVietnamese2013 Pharmacy Student

Laura StintonCaucasianJune 2013Fellowship mentor

CLINICAL EXAM SESSIONS

Participant / Proctor, GI Focused clinical exam session, UCSD, November 2011Participant, Clinical Exam Sessions, University of California, San Diego School of Internal Medicine, November 21, 2011.

1979 1994

1. Stella VJ, Gish RG. Ionization kinetics of the carbon acid phenindione. J Pharm Sci. August 1979; 68(8):1042-1047.2. Stella VJ, Gish RG. Kinetics and mechanism of ionization of the carbon acids 4-substituted 2-phenyl-1, 3-indanediones. J Pharm Sci. August 1979; 68(8):1047-1049.3. Gish RG, Garcia C, Reedy T, Kaplowitz N, Langer GA. Calcium compartmentation and exchange rates in primary hepatocyte culture. Anal Biochem. May 1990; 187(1):187-196.4. Zeldis JB, Depner TA, Kuramoto RK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med. Jun 1990;112(12):958-960.5. Linton MF, Gish RG, Hubl ST, Butler E, Esquivel CO, Boyles JK, Wardell MR, Young SG. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. Jul 1991;88(1):270-281.6. Nakazato P, Cox K, Concepcion W, Gish RG, Berquist W, Imperial J, Esquivel C. Early experience with FK506 induction immunosuppression suggestion for using oral FK506. Transplant Proc. Dec 1991;23(6):3019-3020.7. Gish RG, Warmerdam M, Zeldis J, Keeffe EB, Nakazato P, Lim J, Cox K, Kuramoto IK, Fry KE, Yarbough P, Moeckli R, Yun-cho K, Reyes G. Variation in antibody reactivity to the hepatitis C virus by comparative immunoscreening and enzyme immunoassay. Viral Immunology. Spring 1993;6(1):49-54.8. Gish RG, Lee AH, Keeffe EB, Rome H, Concepcion W, Esquivel CO. Liver transplantation for patients with alcoholism and end-stage liver disease. Am J Gastroenterol. Sep 1993;88(9):1337-1342.9. Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Tsukiyama-Kohara K, Kohara M, Mondelli MU, Lesniewski R, Phillips MI, Mizokami M, et al. Optimization for the detection of viral hepatitis C (HCV) antigens in liver. J Hepatology. Jan 1994;20(1):143-147.10. Lang T, Berquist W, Rich E, Cox K, De Vries P, Cahill J, Baker E, Gish R. Treatment of recurrent pancreatitis by endoscopic drainage of a duodenal duplication. J Pediatr Gastroenterol Nutr. May 1994;18(4):494-496.1995

11. Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Gish RG, Cox K, So S, Esquivel CO, Krams SM. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplant Proc. Feb 1995;27(1):1211-1212.12. Gish RG, Krams S, Martinez OM. Interleukin 12 (IL-12): A possible cytotoxic T-lymphocyte (CTL) differentiation factor in allograft recipients. Transplant Proceed. Feb 1995;27(1):459-460.

Curriculum VitaeROBERT G. GISH, M.D.49PUBLICATIONS: PEER REVIEW ORIGINAL PUBLICATIONS

Curriculum VitaeROBERT G. GISH, M.D.49

BOARD ACTIVITIES: Continued

13. Lau JY, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, Perrill RP, Lindsay KL, Gish RG, Qian KP, Kohara M, Simmonds P, and Urdea MS. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Inf Dis. Feb 1995;171(2):281-289.14. Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol. Mar 1995;22(3):257-262.15. Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Kohara M, Mondelli MU, Urdea MS, Mizokami M, Lau JY. Significance of hepatic expression of hepatitis C viral (HCV) antigens in chronic hepatitis C. Dig Dis Sci. Dec 1995;40(12):2595-2601.199616. Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC, Garcia-Kennedy R, Esquivel CO, Keeffe EB. Ganciclovir treatment of hepatitis B virus infection in liv